Comparable stake leader
ORBIMED ADVISORS LLC
SEC ownership of Electra Therapeutics, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0002088082.
Disclosed value leader
—
Comparable rows
3/14
Latest evidence
21 Sep 2026
- Public ticker
- ETRA
- Parsed ownership sources
-
3/4/5 and 13D/G
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
ORBIMED ADVISORS LLC
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
3 of 14
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
ORBIMED ADVISORS LLC
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
21 Sep 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0002088082
- Issuer location
- South San Francisco, CA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Electra Therapeutics, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
ORBIMED ADVISORS LLC
Disclosed value leader
—
Comparable rows
3/14
Latest evidence
21 Sep 2026
3/4/5
13D/G
Lead comparable stake: 11%
11 rows are not safely comparable across share classes.
13D/G row: ORBIMED ADVISORS LLC
Showing 1-8 of 14 holder rows.
Quick read
ORBIMED ADVISORS LLC leads the comparable SEC ownership view at 11%.
3 of 14 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens ORBIMED ADVISORS LLC's linked filing trail.
Comparable ownership
Top 3
ORBIMED ADVISORS LLC
11%
Redmile Group, LLC
8.7%
7. Cooperative Ua Lsp
6%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 14 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC |
3/4/5
13D/G
Director, 10%+ Owner
|
11%
from 13D/G
|
—
1,758,279 shares
|
— | 21 Sep 2026 |
| Redmile Group, LLC |
13D/G
|
8.7%
|
—
5,462,881 shares
|
$0 | 21 Sep 2026 |
| 7. Cooperative Ua Lsp |
13D/G
LSP 7 Cooperatief U.A.
|
6%
|
—
3,795,281 shares
|
$0 | 21 Sep 2026 |
| Westlake BioPartners Fund I, L.P. |
3/4/5
10%+ Owner
|
—
class O/S missing
|
—
2,820,403 shares
|
— | 21 Sep 2026 |
| Westlake BioPartners Fund II, L.P. |
3/4/5
10%+ Owner
|
—
class O/S missing
|
—
2,820,403 shares
|
— | 21 Sep 2026 |
| Westlake BioPartners GP I, LLC |
3/4/5
10%+ Owner
|
—
class O/S missing
|
—
2,820,403 shares
|
— | 21 Sep 2026 |
| Westlake BioPartners GP II, LLC |
3/4/5
10%+ Owner
|
—
class O/S missing
|
—
2,820,403 shares
|
— | 21 Sep 2026 |
| Carl L. Gordon |
3/4/5
Director, 10%+ Owner
|
—
class O/S missing
|
—
1,758,279 shares
|
— | 21 Sep 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 14 Oct 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-16 of 16 reporting-owner rows connected to Electra Therapeutics, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
16
Largest Forms 3/4/5 holder
Quehuong (kathy) Dong
Net 12M change
$0
Latest report
21 Sep 2026
Recent insider transactions for Electra Therapeutics, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Carl L. Gordon | ETRA | Common Stock | Purchase | 35.2% | 1,333,333 | 5,126,891 | 21 Sep 2026 | See footnotes | ||
| Carl L. Gordon | ETRA | Common Stock | Conversion of derivative security | 5,551,837 | 4,793,558 | 21 Sep 2026 | See footnotes | |||
| Carl L. Gordon | ETRA | Series C Convertible Preferred Stock | Conversion of derivative security | -100% | -2,461,593 | 0 | 21 Sep 2026 | See footnotes | ||
| Carl L. Gordon | ETRA | Series B Convertible Preferred Stock | Conversion of derivative security | -100% | -1,087,934 | 0 | 21 Sep 2026 | See footnotes | ||
| Carl L. Gordon | ETRA | Series A Convertible Preferred Stock | Conversion of derivative security | -100% | -2,002,310 | 0 | 21 Sep 2026 | See footnotes | ||
| Orbimed Advisors Llc | ETRA | Common Stock | Purchase | 35.2% | 1,333,333 | 5,126,891 | 21 Sep 2026 | See footnotes | ||
| Orbimed Advisors Llc | ETRA | Common Stock | Purchase | 35.2% | 1,333,333 | 5,126,891 | 21 Sep 2026 | See footnotes | ||
| Orbimed Advisors Llc | ETRA | Common Stock | Purchase | 35.2% | 1,333,333 | 5,126,891 | 21 Sep 2026 | See footnotes | ||
| Orbimed Advisors Llc | ETRA | Common Stock | Conversion of derivative security | 5,551,837 | 4,793,558 | 21 Sep 2026 | See footnotes | |||
| Orbimed Advisors Llc | ETRA | Common Stock | Conversion of derivative security | 5,551,837 | 4,793,558 | 21 Sep 2026 | See footnotes | |||
| Orbimed Advisors Llc | ETRA | Common Stock | Conversion of derivative security | 5,551,837 | 4,793,558 | 21 Sep 2026 | See footnotes | |||
| Orbimed Advisors Llc | ETRA | Series C Convertible Preferred Stock | Conversion of derivative security | -100% | -2,461,593 | 0 | 21 Sep 2026 | See footnotes | ||
| Orbimed Advisors Llc | ETRA | Series C Convertible Preferred Stock | Conversion of derivative security | -100% | -2,461,593 | 0 | 21 Sep 2026 | See footnotes | ||
| Orbimed Advisors Llc | ETRA | Series C Convertible Preferred Stock | Conversion of derivative security | -100% | -2,461,593 | 0 | 21 Sep 2026 | See footnotes | ||
| Orbimed Advisors Llc | ETRA | Series B Convertible Preferred Stock | Conversion of derivative security | -100% | -1,087,934 | 0 | 21 Sep 2026 | See footnotes | ||
| Orbimed Advisors Llc | ETRA | Series B Convertible Preferred Stock | Conversion of derivative security | -100% | -1,087,934 | 0 | 21 Sep 2026 | See footnotes | ||
| Orbimed Advisors Llc | ETRA | Series B Convertible Preferred Stock | Conversion of derivative security | -100% | -1,087,934 | 0 | 21 Sep 2026 | See footnotes | ||
| Orbimed Advisors Llc | ETRA | Series A Convertible Preferred Stock | Conversion of derivative security | -100% | -2,002,310 | 0 | 21 Sep 2026 | See footnotes | ||
| Orbimed Advisors Llc | ETRA | Series A Convertible Preferred Stock | Conversion of derivative security | -100% | -2,002,310 | 0 | 21 Sep 2026 | See footnotes | ||
| Orbimed Advisors Llc | ETRA | Series A Convertible Preferred Stock | Conversion of derivative security | -100% | -2,002,310 | 0 | 21 Sep 2026 | See footnotes | ||
| Gary S. Koe | ETRA | Common Stock | Conversion of derivative security | 63,656 | 63,656 | 21 Sep 2026 | Direct | |||
| Gary S. Koe | ETRA | Series A Convertible Preferred Stock | Conversion of derivative security | -100% | -63,656 | 0 | 21 Sep 2026 | Direct | ||
| Nancy Stagliano | ETRA | Common Stock | Conversion of derivative security | 255,635 | 255,635 | 21 Sep 2026 | Direct | |||
| Nancy Stagliano | ETRA | Series A Convertible Preferred Stock | Conversion of derivative security | -100% | -255,635 | 0 | 21 Sep 2026 | Direct | ||
| Graham Parry | ETRA | Common Stock | Conversion of derivative security | 85,504 | 85,504 | 21 Sep 2026 | Direct | |||
| Graham Parry | ETRA | Series A Convertible Preferred Stock | Conversion of derivative security | -100% | -85,504 | 0 | 21 Sep 2026 | Direct | ||
| Quehuong (kathy) Dong | ETRA | Common Stock | Conversion of derivative security | 455,484 | 455,484 | 21 Sep 2026 | Direct | |||
| Quehuong (kathy) Dong | ETRA | Series A Convertible Preferred Stock | Conversion of derivative security | -100% | -455,484 | 0 | 21 Sep 2026 | Direct |
* marks a reported price that did not pass the local price check.